Back to top
more

DexCom (DXCM)

(Delayed Data from NSDQ)

$65.68 USD

65.68
3,456,884

-1.42 (-2.12%)

Updated Oct 3, 2024 04:00 PM ET

After-Market: $65.69 +0.01 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 23% (59 out of 252)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Shockwave Medical (SWAV) Q3 Earnings Beat, Revenues Rise Y/Y

Shockwave Medical's (SWAV) third-quarter results reflect robust revenue growth and gross margin expansion on the back of strong demand and new launches.

Insulet (PODD) Banks on Omnipod for Consistent Market Share Gain

Insulet's (PODD) Omnipod 5 continues to be a driving force behind U.S. and international growth.

QIAGEN (QGEN) Launches Workflow to Boost Microbiome Research

QIAGEN (QGEN) expands the Microbiome solutions portfolio with the launch of Microbiome WGS SeqSets.

Here's Why You Should Retain Tandem Diabetes (TNDM) Now

Investors remain optimistic about Tandem Diabetes (TNDM), backed by upcoming innovative launches, including Mobi and the new integrated CGM offering.

QIAGEN's (QGEN) Molecular Diagnostics Gains Share, FX Woe Stays

QIAGEN (QGEN) continues to see a very healthy conversion trend from the tuberculin skin test.

Bruker (BRKR) Q3 Earnings and Revenues Top, '23 Sales View Up

Bruker (BRKR) delivers better-than-expected earnings and revenues in the third quarter of 2023.

Inari Medical (NARI) Q3 Earnings and Revenues Beat Estimates

Inari Medical's (NARI) third-quarter results benefit from strong product adoption and geographical performances.

AMN Healthcare (AMN) Q3 Earnings and Revenues Beat Estimates

AMN Healthcare's (AMN) dismal results in all its segments led to a soft overall third-quarter performance.

Cardinal Health (CAH) Beats on Q1 Earnings, Ups '24 EPS View

Cardinal Health's (CAH) first-quarter fiscal 2024 results benefit from the Pharmaceutical segment's solid performance.

Stryker (SYK) Q3 Earnings Beat on Strong Segmental Result

Stryker's (SYK) third-quarter earnings reflect strong performance across its segments and geographies. However, unfavorable currency movement hurts sales growth, and rising costs affect margins.

Fresenius Medical (FMS) Q3 Earnings Miss, Operating Margin Up

Fresenius Medical's (FMS) third-quarter revenues suffer due to unfavorable currency movement. However, the company's transformational plans continue to benefit its operating income.

Prestige Consumer (PBH) Q2 Revenues Top, Margins Expand

Prestige Consumer's (PBH) second-quarter fiscal 2024 results benefit from a diverse brand portfolio and broad distribution.

Omnicell (OMCL) Q3 Earnings and Revenues Beat, Margins Down

Omnicell's (OMCL) third-quarter 2023 results reflect operational discipline in a weak demand environment.

Avanos (AVNS) Q3 Earnings Top Estimates, Margins Contract

Despite strength in Avanos' (AVNS) Digestive Health segment, its overall third-quarter results reflect soft performances.

QuidelOrtho (QDEL) Q3 Earnings Top Estimates, Margins Down

Despite solid performances by the Labs and TM segments and China and Other regions, QuidelOrtho (QDEL) reports soft overall top-line results in third-quarter 2023.

Why DexCom (DXCM) Might be Well Poised for a Surge

DexCom (DXCM) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Nevro (NVRO) Q3 Earnings Top Estimates, FY23 Revenue View Up

Nevro's (NVRO) worldwide revenues improve on a year-over-year basis in the third quarter, owing to robust domestic performance.

Cencora (COR) Q4 Earnings Top, GLP-1 Drugs Boost Sales

Cencora's (COR) fourth-quarter fiscal 2023 results benefit from overall market growth, including rising demand for GLP-1 drugs approved for diabetes and weight loss. Inflationary pressure remains.

Baxter (BAX) Beats on Q3 Earnings, Divests BioPharma Business

Baxter (BAX) reports better-than-expected third-quarter earnings and sales. The company completes the divestment of its BioPharma Solution business. It starts reporting under a new operating model.

DENTSPLY SIRONA (XRAY) Beats on Q3 Earnings, Lowers '23 Guidance

DENTSPLY SIRONA's (XRAY) Q3 revenues are driven by a rise in demand for aligners and CAD/CAM in the United States and a recovery in demand in China. Challenging macro headwinds linger.

Glaukos (GKOS) Q3 Earnings Beat Estimates, Revenues Rise Y/Y

Glaukos' (GKOS) third-quarter revenues beat estimates but fall year over year. Sales and gross margin improve, while higher operating expenses lead to a wider operating loss.

McKesson (MCK) Beats on Q2 Earnings, Raises '23 EPS View

McKesson's (MCK) second-quarter fiscal 2024 results benefit from growth in the United States. Divestment hurts the International segment.

Wall Street Analysts Think DexCom (DXCM) Could Surge 36.81%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 36.8% in DexCom (DXCM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

DexCom (DXCM) Just Reclaimed the 50-Day Moving Average

Good things could be on the horizon when a stock surpasses the 50-Day simple moving average. How should investors react?

Tandem Diabetes (TNDM) Posts Wider Q3 Loss, Trims '23 Sales View

Tandem Diabetes (TNDM) reports a higher-than-anticipated loss in the third quarter of 2023.